Labcorp (LH) said Monday it has made available the Labcorp Plasma Complete, a circulating tumor DNA-based test for patients with advanced solid tumors.
The test detects genomic alterations across 521 genes, including biomarkers associated with FDA-approved treatments.
The liquid biopsy test allows oncologists to profile patients from blood samples and draw up personalized treatments, the healthcare company said.
LH shares were 0.1% higher in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。